Pemvidutide is an investigational peptide developed by Altimmune that activates both the glucagon receptor and the GLP-1 receptor in a deliberately balanced, roughly 1:1 ratio. That balance is the drug's defining design choice, and it's what separates it from most other dual agonists in development, many of which lean more heavily toward one receptor or the other.
What It Is and How It Works
GLP-1 receptor activation is the mechanism behind approved drugs like semaglutide and reduces appetite and slows gastric emptying. Glucagon receptor activation is a different lever: it increases energy expenditure and has direct effects on liver fat metabolism. By dialing both receptors up together, Altimmune is aiming for a drug that pairs GLP-1's appetite-suppressing effect with glucagon's more liver-specific fat-burning effect, which is the rationale behind testing it specifically for liver disease rather than obesity alone.
Regulatory Status
Pemvidutide is not FDA-approved for any use. It remains an investigational drug in clinical development, evaluated so far in Phase 2 trials for metabolic dysfunction-associated steatohepatitis (MASH, formerly called NASH) and separately for alcohol use disorder and alcohol-associated liver disease. It is not available by prescription and is not a product legitimately sold as a research chemical, since it's an active clinical candidate still under Altimmune's exclusive development.
What the MASH Research Shows
The most substantial data comes from the Phase 2b IMPACT trial, a randomized, double-blind, placebo-controlled study of 212 participants with biopsy-confirmed MASH and moderate to advanced fibrosis (stages F2-F3), followed for 48 weeks. At the 1.8 mg dose, participants saw a reduction in Enhanced Liver Fibrosis score of 0.58 versus a 0.16 increase on placebo, a reduction in liver stiffness measurement of 3.97 versus 0.03 on placebo, and a 54.7% reduction in liver fat content versus 8.2% on placebo, all statistically significant. Average weight loss was 7.5% versus 0.2% on placebo over the same period. Reported discontinuations due to adverse events were low in both arms, 1.2% on the 1.8 mg dose versus 3.5% on placebo, though this remains human clinical-trial data from a single Phase 2b study, not an approval-level evidence base.
The Alcohol Use Disorder Angle
Separately, Altimmune has reported trial data suggesting pemvidutide reduced heavy drinking days in a study of people with alcohol use disorder, an application that reflects broader research interest in whether GLP-1 and glucagon receptor pathways affect reward-related behaviors beyond appetite. This remains earlier-stage, exploratory research relative to the MASH program, and no drug in this class is approved for treating alcohol use disorder.
Where the Program Stands
Altimmune reported in December 2025 that it had reached alignment with the FDA on the design of a registrational Phase 3 trial for MASH patients with moderate to advanced fibrosis, with plans to begin that Phase 3 program in 2026. Reaching FDA alignment on trial design is a meaningful regulatory step, but it is not the same as approval, and a successful Phase 3 program, FDA review, and formal approval would all still need to happen before pemvidutide could reach patients as a prescribed medication.
The Bottom Line
Pemvidutide represents a genuinely different design philosophy from single-target GLP-1 drugs, aimed specifically at liver disease rather than obesity as a first indication, with encouraging but still Phase 2-level human data behind it. It is not FDA-approved, not available for prescription, and its eventual approval and labeled use, if any, will depend on Phase 3 results that haven't yet been generated. Anyone following this space for a family member with MASH or heavy drinking concerns should treat it as a drug in development to watch, not a current treatment option, and should talk to a physician about currently available options.